Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

CAMBRIDGE, Mass. and KRAKOW, Poland, Sept. 16, 2013 /PRNewswire/ -- H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, announced today that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

Recent advances in human cancer genomics have revealed novel target opportunities that will enable new approaches to developing cancer medicines. H3 Biomedicine has built extensive and proprietary target acumen. It has also implemented a set of unique tools and research engines in the areas of cancer genomics, bioinformatics and target validation to lend biological insight to genomic findings. These capabilities will help to accelerate its collaborative drug discovery and development efforts. Selvita started its first kinase discovery programs in 2008 and, over the last five years, has built a premium scientific team with one of the world's most robust kinase discovery platforms. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.

"Our goal at H3 Biomedicine is to – in a very focused way – utilize the genomic information from public and proprietary data sets to identify and validate highly relevant cancer genes and to develop effective therapies against those targets," stated

SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, ... in Miami.   The live presentation takes ... PT).  The presentation will be webcast and may be ... Listeners are encouraged to visit the ...
(Date:3/3/2015)... March 03, 2015 BlueInGreen ... to their international sales network. The business venture ... technology to Canada’s Atlantic Provinces, exclusively through Resource ... as one of Canada’s premiere manufacturing representative firms, ... the municipal water and wastewater markets. More information ...
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
Breaking Biology Technology:BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Oct. 22 Medivation, Inc.,(Nasdaq: MDVN ) ... Antitrust Improvements Act for its collaboration with,Pfizer Inc. ... and Pfizer have agreed to jointly develop and ... Huntington,s disease.,Expiration of the waiting period triggers an ...
... Encouraging and Durable Anti-Tumor Activity and ... Dose Escalation Continues -, - Results Presented at the 20th ... Targets and Cancer Therapeutics ... ) today announced the presentation of new data from an,ongoing Phase 1-2 clinical ...
... Results Enable Physicians to Direct Earlier, Effective, Antimicrobial Therapy ... ... Lives(1), WOBURN, Mass., Oct. 22 AdvanDx today announced ... test reduced,mortality by 42% for patients with highly drug resistant ...
Cached Biology Technology:Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4AdvanDx's PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections 2AdvanDx's PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections 3AdvanDx's PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections 4AdvanDx's PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections 5
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... EAST LANSING, Mich. Monitoring oxygen levels in ... beer and more and a professor at Michigan ... The concept of oxygen sensors isn,t new. The ... fluctuations in temperature, salinity, carbon dioxide, phosphates and biological ...
... larvae ( Chaoborus spp.) may explain a few hundred ... and fish death in Swedish lakes. Researchers at the University ... sediments to show when and how fish life disappeared from ... regions. "It is actually just like a journey ...
... Laboratories at the University of New Mexico (UNM), Brown ... technique to observe herpes simplex virus type 1 (HSV1) infections ... sore, persists in a latent form inside nerve cells. Re-activation ... with Alzheimer,s disease. Details are published in the March 31 ...
Cached Biology News:Oxygen sensor invention could benefit fisheries to breweries 2Dead midges reveal living conditions of fish 2Researchers link herpes to Alzheimer's disease 2
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... in RPMI 1640 with 2 mM L-glutamine and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... Novagen's frozen Sf9 Insect Cells are derived ... are pretested for optimal growth, use in transfections, ... cells are frozen in a protocol that optimizes ... adapted for growth in serum-free BacVector Insect Cell ...
... package that provides crystallographers with an ... creation, set-up of experimental conditions and ... software helps crystallographers through the most ... Design of Crystallization ...
Biology Products: